Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,348 recruiting studies in this area right now.
By phase
- Not applicable9,612
- Phase 24,442
- Phase 12,685
- Phase 1/Phase 21,654
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer648
- Cancer636
- Colorectal Cancer476
- Lung Cancer421
- Ovarian Cancer341
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma259
- Solid Tumor245
- Advanced Solid Tumor231
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors208
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,401
- Texas636
- Arizona508
- Florida439
- Alabama430
- New York406
- Massachusetts340
- Maryland330
- New Jersey275
- Pennsylvania236
Recruiting studies20,348 total
- NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT05963867RecruitingPhase 1
First-dose study of a cancer drug taken up by tumors
This Phase 1 study tests how BI 764532 moves into and through tumors in people with small-cell lung cancer or neuroendocrine cancer. It’s likely aimed at understanding the drug’s behavior in your body and tumor, especially if you’ve already tried standard treatments.
AmsterdamAges 18 years+ - NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05957081RecruitingPhase 1
Safety and drug level study of PMC-309 in advanced tumors
This Phase 1 trial tests how safe PMC-309 is and how the drug behaves in the body (blood levels) in people with advanced or metastatic solid tumors. Because it’s an early study, the main goal is to find safe dosing and gather information that could guide future treatments.
Benowa, QueenslandAges 18 years+ - NCT05965557Recruiting
Markers that predict response to immunotherapy before lung surgery
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
ShanghaiAges 18–80 - NCT05951777RecruitingPhase 2
Stem cells from your own fat for chronic brain injury
This trial tests whether stem cells taken from your own fat and given through an IV can help people with long-term brain damage from a head injury. It is for adults who have not gotten better with standard treatments.
Houston, TexasAges 18–55 - NCT04945148RecruitingPhase 2
Metformin plus radiation and chemo for glioblastoma subtype
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
Suresnes, Hauts de SeineAges 18 years+ - NCT05566054RecruitingPhase 2
Newly diagnosed AML-M5 treated with VAC drug combination
This Phase 2 trial studies a combination of Venetoclax, Azacitidine, and Chidamide (VAC) for newly diagnosed acute monocytic leukemia (AML-M5). It may help people who cannot safely receive standard “intensive chemotherapy” because of age or other health problems.
Suzhou, JiangsuAges 18 years+ - NCT05940961RecruitingPhase 2
Inotuzumab for MRD-positive B-cell leukemia after transplant
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
Suzhou, JiangsuAges 15–65 - NCT04081701RecruitingPhase 4
Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
New York, New YorkAges 18–100 - NCT05730816RecruitingPhase 2
Magnesium to help protect kidneys during high-risk chest surgery
This Phase 2 trial studies whether giving magnesium by IV can help prevent sudden kidney injury around the time of certain major chest (thoracic) cancer surgeries. If you qualify, you may receive magnesium or a comparison treatment to see if kidney protection improves after surgery.
Boston, MassachusettsAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Tucson, ArizonaAges 18 years+ - NCT05146778Recruiting
Opioid-free anesthesia to reduce long-term post-mastectomy pain
This study tests whether a pain-control approach without opioids (strong pain medicines) can lower persistent pain after mastectomy. It may help people avoid long-term pain and opioid side effects.
SeoulAges 19–80 - NCT05267041Recruiting
Lung cancer database study at Lyon hospitals
This study collects information about people who have been treated for lung or chest cancers at Lyon University Hospital. Your data may help researchers better understand these cancers and improve future care.
Pierre-BéniteAges 18 years+ - NCT05800535Recruiting
Screening for muscle loss and thinking changes after cancer
This study looks at how common muscle weakness (sarcopenia) and thinking or memory changes (often called “chemobrain”) are in people after cancer treatment. It may help teams understand what support could be most helpful after chemotherapy.
Pierre-BéniteAges 18–74 - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Duarte, CaliforniaAges 35 years+ - NCT05912257Recruiting
Nutrition program before and after surgery to protect function
This study tests whether an “optimizing nutrition” plan before and after cancer surgery can help older adults maintain physical strength and daily functioning. You may be randomly assigned to the nutrition program or another study group, and you’ll be asked about diet and physical function.
Durham, North CarolinaAges 55 years+ - NCT05926102Recruiting
Screening study for prostate cancer risk and access
This study looks at how genetic risk and regular screening can help find prostate cancer earlier. It may help you and other Veterans understand what screening is best for different risk levels and access needs.
Boston, MassachusettsAges 55–69 - NCT05927571RecruitingPhase 1
Cevostamab and elranatamab combination study for relapsed myeloma
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
Camperdown, New South WalesAges 18 years+ - NCT05919238RecruitingPhase 1
Padeliporfin treatment for non-removable pancreatic cancer
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Duarte, CaliforniaAges 18 years+ - NCT05935384Recruiting
Blood tests to track response to cancer therapy
This study follows how cancer responds to standard (usual) treatment by using blood samples and de-identified health data. It may help researchers understand whether “liquid biopsy” blood testing can reflect how well therapy is working.
Skokie, IllinoisAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT05914545RecruitingPhase 1
Early study drug for advanced solid tumors in adults
This Phase 1 trial tests a new experimental medicine (FZ-AD004) in adults with advanced solid tumors. It aims to see how the drug behaves in the body and whether it’s safe enough to continue in patients with measurable cancer.
HangzhouAges 18–75 - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
Fayetteville, ArkansasAges 18–100
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,348 recruiting oncology studies from the U.S. registry right now, out of 31,535 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.